Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2018-05-23 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Uchwały podjęte przez Zwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 23 maja 2018 r. - Content (PL)
AGM Information Classification · 98% confidence The document text is very short (380 characters) and explicitly states that the management ('Zarząd') is attaching the content of the resolutions ('treść uchwał') adopted by the Annual General Meeting ('Zwyczajne Walne Zgromadzenie Spółki') on May 23, 2018. This structure—announcing the results/content of a shareholder meeting—is characteristic of reporting the outcome of an AGM. Since it is an announcement of the resolutions passed at the AGM, the most appropriate code is AGM-R (AGM Information), which covers presentations and materials shared during the AGM. It is not a DVA (Declaration of Voting Results) because it focuses on the content of the resolutions themselves rather than just the vote tally, although there is overlap. Given the context of providing the 'content of the resolutions' from the AGM, AGM-R is the best fit.
2018-05-23 Polish
Uchwała Zwyczajnego Walnego Zgromadzenia Spółki w sprawie wypłaty dywidendy - Content (PL)
Notice of Dividend Amount Classification · 99% confidence The document text explicitly discusses the resolutions passed by the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie - ZWZ) regarding the distribution of the net profit for 2017. Specifically, it details the allocation of profit to the reserve capital and the declaration of a dividend, including the amount per share, the record date (dzień dywidendy), and the payment date (termin wypłaty dywidendy). This content directly relates to the outcome of a shareholder vote concerning financial distribution, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the final decision made by the AGM on a key matter (dividend allocation). While it mentions the AGM, the core information is the result of the vote on profit distribution.
2018-05-23 Polish
Zakończenie III części badania klinicznego I fazy nad lekiem opartym na Esketaminie - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a brief announcement (982 characters) from Celon Pharma S.A. regarding the completion of the third part of Phase I clinical trials for an Esketamine-based drug. It references a previous current report and states that the company has concluded this clinical phase and will now analyze the data to design the next stage (Phase II). Since this is a specific update on clinical trial progress, and not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), it best fits the category for updates on specific company activities or regulatory milestones. Given the options, this type of specific operational/R&D update that isn't explicitly covered by other codes (like M&A, Capital, or Management changes) falls under the general 'Regulatory Filings' (RNS) as a specific regulatory/operational update, or potentially 'LTR' if it were legal, but here it is R&D progress. However, since it is a specific update on a clinical trial milestone, and not a general announcement of a report being available (RPA), RNS is the most appropriate fallback for specific, non-standard operational news that doesn't fit the other defined categories like DIV, DIRS, or MANG. Given the context of clinical trial updates, which are often mandatory disclosures, RNS serves as the best fit among the provided codes for this specific operational news update.
2018-05-22 Polish
Sprawozdanie RN za rok 2017
Board/Management Information Classification · 99% confidence The document is titled "ROCZNE PISEMNE SPRAWOZDANIE RADY NADZORCZEJ CELON PHARMA SPÓŁKA AKCYJNA ZA ROK 2017" which translates to "ANNUAL WRITTEN REPORT OF THE SUPERVISORY BOARD OF CELON PHARMA S.A. FOR THE YEAR 2017". It covers the fiscal year 2017 (January 1 to December 31, 2017), discusses the Supervisory Board's activities, internal controls, risk management, and provides an opinion on the financial statements and management report for the year. This content strongly aligns with the scope of an Annual Report, specifically the supervisory board's review component, which is typically included within or closely associated with the comprehensive annual filing. While the title specifically mentions the Supervisory Board Report, the content covers the full scope of annual review, including the audit opinion review and dividend proposal review for the entire fiscal year. In the context of standard regulatory filings, this comprehensive annual review document is best classified as the Annual Report (10-K equivalent for Polish context, or a comprehensive annual filing). It is not an Earnings Release (ER) as it is a detailed supervisory board report, not just highlights. It is not an Audit Report (AR) as it is broader, covering governance and management review. It is not a Report Publication Announcement (RPA) because it contains the substantive content of the annual review, not just an announcement that a report is available. Therefore, 10-K is the most appropriate classification for a comprehensive annual performance review document.
2018-05-21 Polish
Uzupełnienie dokumentacji na Zwyczajne Walne Zgromadzenie Celon Pharma S.A. zwołane na dzień 23 maja 2018 roku - Content (PL)
AGM Information Classification · 95% confidence The document text is very short (416 characters) and explicitly refers to a previous announcement (raport bieżący nr 13/2018) concerning the upcoming Annual General Meeting (Zwyczajne Walne Zgromadzenie). The core purpose of this text is to inform that the Management Board is attaching the Supervisory Board's Report for 2017 ('Sprawozdanie Rady Nadzorczej Spółki za rok 2017') for consideration at the AGM. Since this is an announcement about the publication/attachment of a report rather than the report itself, and it relates to materials for a general meeting, the most appropriate classification is Report Publication Announcement (RPA). It is not the full AGM material (AGM-R) or the Audit Report (AR) itself, but the notice of its availability.
2018-05-21 Polish
Wydanie przez Prezesa Urzędu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych pozwolenia na prowadzenie badania klinicznego. - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (828 characters) and references a prior report (ESPI nr 10/2018) to announce a specific regulatory event: receiving a decision from the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products regarding a clinical trial authorization for GLG-801. This is a specific regulatory update concerning product development/legal status, not a comprehensive financial report (like 10-K or IR) or a general announcement of a report's publication (RPA). Given the specific nature of the update regarding a regulatory decision and clinical trial progress, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement that doesn't map perfectly to the other specific categories like DIRS, DIV, or CAP, although it is a specific regulatory event. Since 'LTR' is for legal proceedings/lawsuits, and this is a positive regulatory approval/decision, RNS serves as the most appropriate general regulatory filing category.
2018-05-18 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.